This funding opportunity supports exploratory and developmental phased clinical trial research (R61/R33) aimed at treating critical and co-occurring health conditions in individuals with Down syndrome. It provides up to two years for preliminary studies followed by up to three years for clinical trial support, with a total project period not exceeding five years. Applications must include measurable milestones and focus on improving health and quality of life for this population.
Eligible applicants include a wide range of organizations such as city, county, state governments, nonprofits, tribal organizations, institutions of higher education, small businesses, and foreign entities. Both domestic and foreign organizations may apply.
